GENERAL INFORMATION
The seed fund program has been renamed to honor Prof. Lesley Jones. Lesley was deeply involved in the review of these applications, first as an SBAC member and Chair and later as an EC member.
Seed funds up to a limit of €50,000 are intended to fast-track pilot studies required to apply for larger grants from other organisations, or to estimate the statistical power needed for larger studies (e.g., in clinical trials). Studies funded through this scheme should result in conclusive answers to the hypotheses under test. Any European EHDN member can apply, however we especially encourage applications from working groups to stimulate discussion and collaboration within those groups while reducing any overlap between projects proposed by individual members. Seed funds are awarded twice a year.
Calls for seed fund applications for 2024:
1st March, at 23:59 CET
1st November, at 23:59 CET
ELIGIBILITY CRITERIA
EHDN will award seed funds on a competitive basis amongst the submissions received at each deadline. Basic and clinical projects are welcome.
Proposals rejected at a previous round of applications will not be reconsidered. Amended versions will be treated as new submissions.
Submissions received after the deadline or incomplete submissions (e.g. CVs for applicants or co-applicants missing, use of wrong application form, word count over the maximum in any section…) will not be considered and will only be reviewed during the next round. Recipients of seed funds cannot submit a new application unless they have provided a report that concludes their previously awarded seed fund project. Only European projects are eligible; the main PI has to be an EHDN regular member, based in Europe, and at least 50% of the funds must stay in Europe. All co-applicants have to be EHDN members (either regular or associated) and listed in the online submission form.
In the context of your research, questions about intellectual property can arise. Should you be awarded a seed fund, a contract with Ulm University as the legal representative of EHDN will need to be signed. This contract will address those questions as they pertain to for instance Disclosure of Inventions, Ownership of Intellectual Property, or a Covenant not to Seek Intellectual Property Protection. It is important for EHDN that everything that will come out of your project (e.g. data, results, assay, novel treatment, etc) can be shared for HD research and education.
APPLICATION REVIEW PROCESS
Every application will be reviewed by the Scientific and Bioethics Advisory Committee (SBAC).
The SBAC considers the aims, objectives, scientific and clinical merits of the applications, qualifications and capabilities of the investigators and the report of the bioethics advisor. Some criteria for the review of the applications are:
Originality / "out-of-the-box", potential to generate more regular additional funding, potential impact, clear hypothesis and research question, background information, relevant previous and ongoing work considered, methods ade-quate to test hypothesis, resources and expertise to carry out this project successfully, statistics, costs, ethics and any other factors it deems appropriate.
SBAC’s recommendations will then be available to the EHDN Executive Committee. The final decision regarding endorsement of an application rests with the EHDN executive committee, also taking into account EHDN's Scientific Strategic Plan.
Applicants will be informed about the progress of their application.
If applications are endorsed, access to data and/or biomaterials will be granted provided the applicants agree to/that:
1. The Data Disclosure Agreement, Material Transfer Agreement, or Research Agreement.
2. The data from the EHDN database/biomaterials provided will be used for no other purposes than the ones specified in the proposal.
3. The publication policy will be followed.
4. A summary of the project will be posted on the ‘studies in progress’ area of the EHDN public website. The announcement should be no longer than 100 words and describe in simple words (comprehensible for the lay audience) the aims and methods of the project.
PROGRESS REPORTS
If successful in securing funding, applicants need to provide two reports summarising the work that has been accomplished.
An interim report consisting of two parts:
- a summary of work accomplished in the last 6 months
- work planned for the next 6 months
A final report with the results of the study.
This should detail the objectives, material and methods, results, discussion and conclusions. If you have already submitted or published an abstract or publication, please upload it as well. Please do NOT use the publication itself as final report.
In case of any questions or difficulties using this form, please contact Dr Kinga Kołodziej (kmk20@le.ac.uk)